Hutchison MediPharma's plant-derived drug positive at Phase II for ulcerative colitis
This article was originally published in Scrip
Hutchison MediPharma's Chinese herb-derived drug and lead development project, HMPL-004, has met its endpoints in a Phase IIb trial in patients with mild to moderate active ulcerative colitis, show top line data from the completed study.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.